178 related articles for article (PubMed ID: 10235282)
1. Increase of serum des-gamma-carboxy prothrombin in alcoholic liver disease without hepatocellular carcinoma.
Ohhira M; Ohtake T; Saito H; Ikuta K; Tanaka K; Tanabe H; Kawashima T; Fujimoto Y; Naraki T; Ono M; Kohgo Y
Alcohol Clin Exp Res; 1999 Apr; 23(4 Suppl):67S-70S. PubMed ID: 10235282
[TBL] [Abstract][Full Text] [Related]
2. A variant of des-gamma-carboxy prothrombin was increased in alcoholic liver disease without hepatocellular carcinoma.
Ohhira M; Saito H; Suzuki Y; Naraki T; Sakurai S; Ohtake T; Suzuki M; Ohhira M; Fujimoto And Y; Kohgo Y
Alcohol Clin Exp Res; 2001 Jun; 25(6 Suppl):46S-50S. PubMed ID: 11410741
[TBL] [Abstract][Full Text] [Related]
3. Measurement of serum levels of des-gamma-carboxy prothrombin in patients with hepatocellular carcinoma by a revised enzyme immunoassay kit with increased sensitivity.
Okuda H; Nakanishi T; Takatsu K; Saito A; Hayashi N; Watanabe K; Magario N; Yokoo T; Naraki T
Cancer; 1999 Feb; 85(4):812-8. PubMed ID: 10091758
[TBL] [Abstract][Full Text] [Related]
4. The usefulness of determining des-gamma-carboxy prothrombin by sensitive enzyme immunoassay in the early diagnosis of patients with hepatocellular carcinoma.
Mita Y; Aoyagi Y; Yanagi M; Suda T; Suzuki Y; Asakura H
Cancer; 1998 May; 82(9):1643-8. PubMed ID: 9576283
[TBL] [Abstract][Full Text] [Related]
5. Plasma abnormal prothrombin (des-gamma-carboxy prothrombin) as a marker of hepatocellular carcinoma.
Fujiyama S; Morishita T; Hashiguchi O; Sato T
Cancer; 1988 Apr; 61(8):1621-8. PubMed ID: 2450634
[TBL] [Abstract][Full Text] [Related]
6. Abnormal prothrombin (DES-gamma-carboxy prothrombin) in hepatocellular carcinoma.
Nakao A; Virji A; Iwaki Y; Carr B; Iwatsuki S; Starzl E
Hepatogastroenterology; 1991 Oct; 38(5):450-3. PubMed ID: 1722483
[TBL] [Abstract][Full Text] [Related]
7. The influence of alcoholic liver disease on serum PIVKA-II levels in patients without hepatocellular carcinoma.
Kang KH; Kim JH; Kang SH; Lee BJ; Seo YS; Yim HJ; Yeon JE; Park JJ; Kim JS; Bak YT; Byun KS
Gut Liver; 2015 Mar; 9(2):224-30. PubMed ID: 25473073
[TBL] [Abstract][Full Text] [Related]
8. The serum level of NX-DCP-R, but not DCP, is not increased in alcoholic liver disease without hepatocellular carcinoma.
Saito M; Yano Y; Hirano H; Momose K; Mouri K; Hishimoto A; Yoshida M; Azuma T
Cancer Biomark; 2016; 16(1):171-80. PubMed ID: 26600398
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic utility of alpha-fetoprotein and des-gamma-carboxyprothrombin in nigerians with hepatocellular carcinoma.
Ette AI; Ndububa DA; Adekanle O; Ekrikpo U
Niger J Clin Pract; 2017 Oct; 20(10):1267-1272. PubMed ID: 29192630
[TBL] [Abstract][Full Text] [Related]
10. Sequential fluctuation pattern of serum des-gamma-carboxy prothrombin levels detected by high-sensitive electrochemiluminescence system as an early predictive marker for hepatocellular carcinoma in patients with cirrhosis.
Shimizu A; Shiraki K; Ito T; Sugimoto K; Sakai T; Ohmori S; Murata K; Takase K; Tameda Y; Nakano T
Int J Mol Med; 2002 Mar; 9(3):245-50. PubMed ID: 11836630
[TBL] [Abstract][Full Text] [Related]
11. Des-gamma-carboxyprothrombin, alpha-fetoprotein and AFP-L3 in patients with chronic hepatitis, cirrhosis and hepatocellular carcinoma.
Durazo FA; Blatt LM; Corey WG; Lin JH; Han S; Saab S; Busuttil RW; Tong MJ
J Gastroenterol Hepatol; 2008 Oct; 23(10):1541-8. PubMed ID: 18422961
[TBL] [Abstract][Full Text] [Related]
12. Serum des-gamma-carboxyprothrombin concentration determined by the avidin-biotin complex method in small hepatocellular carcinomas.
Saitoh S; Ikeda K; Koida I; Tsubota A; Arase Y; Chayama K; Kumada H
Cancer; 1994 Dec; 74(11):2918-23. PubMed ID: 7525036
[TBL] [Abstract][Full Text] [Related]
13. Novel method to measure serum levels of des-gamma-carboxy prothrombin for hepatocellular carcinoma in patients taking warfarin: a preliminary report.
Toyoda H; Kumada T; Osaki Y; Tada T; Kaneoka Y; Maeda A
Cancer Sci; 2012 May; 103(5):921-5. PubMed ID: 22320249
[TBL] [Abstract][Full Text] [Related]
14. Des-γ-Carboxyprothrombin Plasma Level in Diagnosis of Hepatocellular Carcinoma in a Chinese Population Undergoing Surgery.
Feng X; Song P; Bie P; Jiang P; Ma K; Li X; Wang S; Wang Z; Tang W; Zheng S
Med Sci Monit; 2016 May; 22():1663-72. PubMed ID: 27187589
[TBL] [Abstract][Full Text] [Related]
15. Determination of serum des-gamma-carboxy prothrombin levels in patients with small-sized hepatocellular carcinoma: comparison of the conventional enzyme immunoassay and two modified methods.
Nomura F; Ishijima M; Horikoshi A; Nakai T; Ohnishi K
Am J Gastroenterol; 1996 Jul; 91(7):1380-3. PubMed ID: 8677999
[TBL] [Abstract][Full Text] [Related]
16. [Study on the value of serum des-γ-carboxy prothrombin in predicting hepatocellular carcinoma recurrence after liver transplantation].
Xu Y; Wang PX; Cheng JW; Huang XW; Zhou J; Fan J; Yang XR
Zhonghua Gan Zang Bing Za Zhi; 2020 Nov; 28(11):918-923. PubMed ID: 33256276
[No Abstract] [Full Text] [Related]
17. Application of des-gamma-carboxy prothrombin as a complementary tumor marker with alpha-fetoprotein in the diagnosis of hepatocellular carcinoma.
Ho CH; Lee SD; Chang HT; Wu JC; Tsai YT; Lo KJ
Scand J Gastroenterol; 1989 Jan; 24(1):47-52. PubMed ID: 2467347
[TBL] [Abstract][Full Text] [Related]
18. The Half-Life of Serum Des-Gamma-Carboxy Prothrombin Is a Prognostic Index of Survival and Recurrence After Liver Resection for Hepatocellular Carcinoma.
Okamura Y; Sugiura T; Ito T; Yamamoto Y; Ashida R; Uesaka K
Ann Surg Oncol; 2016 Dec; 23(Suppl 5):921-928. PubMed ID: 27638677
[TBL] [Abstract][Full Text] [Related]
19. Prognostic roles of preoperative α-fetoprotein and des-γ-carboxy prothrombin in hepatocellular carcinoma patients.
Meguro M; Mizuguchi T; Nishidate T; Okita K; Ishii M; Ota S; Ueki T; Akizuki E; Hirata K
World J Gastroenterol; 2015 Apr; 21(16):4933-45. PubMed ID: 25945007
[TBL] [Abstract][Full Text] [Related]
20. Des-γ-carboxy prothrombin ratio measured by P-11 and P-16 antibodies is a novel biomarker for hepatocellular carcinoma.
Tameda M; Shiraki K; Sugimoto K; Ogura S; Inagaki Y; Yamamoto N; Ikejiri M; Takei Y; Ito M; Nobori T
Cancer Sci; 2013 Jun; 104(6):725-31. PubMed ID: 23480217
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
